JAK2V617F allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy

G. Barosi, C. Klersy, L. Villani, E. Bonetti, P. Catarsi, V. Poletto, R. Campanelli, S. Impera, R. Latagliata, G. Viarengo, A. Carolei, M. Massa, M. Musso, A. Crescimanno, R. P. Gale, V. Rosti

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
Publication statusAccepted/In press - Feb 29 2016

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this